<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00175812</url>
  </required_header>
  <id_info>
    <org_study_id>REK-Vestnr21503</org_study_id>
    <nct_id>NCT00175812</nct_id>
  </id_info>
  <brief_title>Differentiation Induction in Acute Myelogenous Leukemia</brief_title>
  <official_title>Differentiation Induction Therapy for Acute Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bergen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Differentiation induction therapy in acute myelogenous leukemia (AML) can be used
      to achieve disease control and stabilize peripheral blood counts in patients with acute
      myelogenous leukemia.

      Adult patients (&lt;18 years of age) who can be included: Elderly patients (&gt;60 years of age)
      with newly diagnosed AML who cannot achieve standard chemotherapy, patients with relapsed or
      resistant AML. Patients with relapsed or resistant AML who cannot receive intensive
      chemotherapy.

      Treatment: Patients will be treated with all-trans retinoic acid (oral administration),
      valproic acid (7 days intravenous administration and later oral administration)and
      theophyllamine (7 days intravenous administration and later oral administration). Duration of
      treatment at least 2 months or until disease progression. Maximal duration of treatment 2
      years.

      Followup: Clinical evaluation, peripheral blood samples, bone marrow samples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients to be included:

        1. Elderly patients above 60 years of age with newly diagnosed acute myelogenous leukemia
           (AML) who cannot receive conventional intensive chemotherapy.

        2. Adult patients of any age (&gt; 18 years of age)with relapsed or resistant AML who cannot
           receive conventional intensive chemotherapy or allogeneic stem cell transplantation.

      We plan to include at least 20 patients, but if possible 30 patients during a 3 years period.
      The first patient was included November 2004.

      Treatment:

      All-trans retinoic acid (ATRA) administered orally 22.5 mg/m2 twice daily for 14 days,
      repeated every third month.

      Valproic acid started on day 3 of ATRA therapy, the first week as intravenous administration
      and later oral administration.

      Theophyllamine started on day 3 of ATRA therapy, the first week as intravenous administration
      and later oral administration.

      Duration of treatment at least 2 months unless side effects,until disease progression or an
      overall duration of treatment of 2 years.

      Supportive therapy according to the hospitals general guidelines.

      Followup:

      The first week treatment in hospital. Later out-patient treatment with regular controls
      including clinical examination, peripheral blood parameters (including serum valproic acid
      and theophyllamin levels), bone marrow samples.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease stabilisation</measure>
    <time_frame>2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease complications</measure>
    <time_frame>2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of therapy</measure>
    <time_frame>2008</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>ATRA plus valproic acid plus theophyllin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATRA for 14 days, continuous treatment with valproic acid and theophyllin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>all-trans retinoic acid (ATRA)</intervention_name>
    <description>All-trans retinoic acid 22.5 mg/square meter twice daily days 1-14</description>
    <arm_group_label>ATRA plus valproic acid plus theophyllin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic acid</intervention_name>
    <description>Valproic acid, highest dose without side effects from day 3 until progression</description>
    <arm_group_label>ATRA plus valproic acid plus theophyllin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophyllin</intervention_name>
    <description>Theophyllin, targetted serum level 50-100 from day 3 until progression</description>
    <arm_group_label>ATRA plus valproic acid plus theophyllin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recently diagnosed acute myelogenous leukemia (AML)

          -  Patients above 60 years of age

          -  Patients who cannot receive conventional chemotherapy

          -  Patients with relapsed or refractory AML independent of age

        Exclusion Criteria:

          -  Chronic myelogenous leukemia in blast phase

          -  Intolerance to the study drugs

          -  Serious liver disease

          -  No informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oystein Bruserud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bergen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haukeland University Hospital, University of Bergen</name>
      <address>
        <city>Bergen</city>
        <zip>N-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res. 2009 Jun;33(6):779-87. doi: 10.1016/j.leukres.2008.10.005. Epub 2008 Nov 12.</citation>
    <PMID>19007987</PMID>
  </results_reference>
  <results_reference>
    <citation>Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT, Bruserud O. In vivo biological effects of ATRA in the treatment of AML. Expert Opin Investig Drugs. 2008 Nov;17(11):1623-33. doi: 10.1517/13543784.17.11.1623 .</citation>
    <PMID>18922099</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bergen</investigator_affiliation>
    <investigator_full_name>Ã˜ystein Bruserud</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Acute myelogenous leukemia</keyword>
  <keyword>Differentiation</keyword>
  <keyword>All trans retinoic acid</keyword>
  <keyword>Valproic acid</keyword>
  <keyword>Theophyllamin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Theophylline</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

